We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols.
- Authors
Rei Umezawa; Keiichi Jingu; Haruo Matsushita; Toshiyuki Sugawara; Masaki Kubozono; Takaya Yamamoto; Yojiro Ishikawa; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Noriyuki Kadoya; Ken Takeda; Hisanori Ariga; Kenji Nemoto; Shogo Yamada; Umezawa, Rei; Jingu, Keiichi; Matsushita, Haruo; Sugawara, Toshiyuki; Kubozono, Masaki
- Abstract
<bold>Background: </bold>To evaluate the long-term results of chemoradiotherapy (CRT) for stage II-III thoracic esophageal cancer mainly by comparing results of three protocols retrospectively.<bold>Methods: </bold>Between 2000 and 2012, 298 patients with stage II-III thoracic esophageal cancer underwent CRT. Patients in Group A received two cycles of cisplatin (CDDP) at 70 mg/m(2) (day 1 and 29) and 5-fluorouracil (5-FU) at 700 mg/m(2)/24 h (day 1-4 and 29-32) with radiotherapy (RT) of 60 Gy without a break. Patients in Group B received two cycles of CDDP at 40 mg/m(2) (day 1, 8, 36 and 43) and 5-FU at 400 mg/m(2)/24 h (day 1-5, 8-12, 36-40 and 43-47) with RT of 60 Gy with a 2-week break. Patients in Group C received two cycles of nedaplatin at 70 mg/m(2) (day 1 and 29) and 5-FU at 500 mg/m(2)/24 h (day 1-4 and 29-32) with RT of 60-70 Gy without a break. Differences in prognostic factors between the groups were analyzed by univariate and multivariate analyses.<bold>Results: </bold>The 5-year overall survival rates for patients in Group A, Group B and Group C were 52.4, 45.2 and 37.2%, respectively. The 5-year overall survival rates for patients in Stage II, Stage III (non-T4) and Stage III (T4) were 64.0, 40.1 and 22.5%, respectively. The 5-year overall survival rates for patients who received 1 cycle and 2 cycles of concomitant chemotherapy were 27.9 and 46.0%, respectively. In univariate analysis, stage, performance status and number of concomitant chemotherapy cycles were significant prognostic factors (p < 0.001, p = 0.008 and p < 0.001, respectively). In multivariate analysis, stage, protocol and number of concomitant chemotherapy cycles were significant factors (p < 0.001, p = 0.043 and p < 0.001, respectively).<bold>Conclusions: </bold>The protocol used in Group A may be an effective protocol of CRT for esophageal cancer. It may be important to complete the scheduled concomitant chemotherapy with the appropriate intensity of CRT.
- Subjects
ESOPHAGEAL cancer; SQUAMOUS cell carcinoma; CANCER chemotherapy; RADIOTHERAPY; UNIVARIATE analysis; MULTIVARIATE analysis; RETROSPECTIVE studies
- Publication
BMC Cancer, 2015, Vol 15, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-015-1836-2